Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Kolumbiens nächster Kupferriese? Warum Investoren dieses 14.000-Meter-Bohrprogramm beobachten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40R8R | ISIN: US6273333053 | Ticker-Symbol: 0XJ0
NASDAQ
13.11.24
21:59 Uhr
3,550 US-Dollar
-0,240
-6,33 %
1-Jahres-Chart
SADOT GROUP INC Chart 1 Jahr
5-Tage-Chart
SADOT GROUP INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,0000,00013.11.
ACCESSWIRE
201 Leser
Artikel bewerten:
(1)

Sadot Group Inc.: Sadot Group, Inc. Reports Third Quarter 2024 Results

Finanznachrichten News

Reports Quarterly Net Income of $1.2 million

BURLESON, TX / ACCESSWIRE / November 12, 2024 / Sadot Group Inc. (Nasdaq:SDOT) ("Sadot Group", "Sadot" or the "Company"), an emerging player in the global food supply chain sector, today announced its financial results for the third quarter ended September 30, 2024.

Third Quarter 2024 Financial Highlights

  • Consolidated revenues of $201.7 million, a 10.7% increase over the prior year period.

  • Net income increased to $1.2 million, up from a $5.2 million loss in the prior year period, a significant improvement of $6.3 million.

  • EBITDA of $2.9 million compared to a negative $4.4 million of EBITDA in the prior year period, a significant improvement of $7.4 million.

  • Basic EPS improved to $0.25 compared to a negative $1.39 in the prior year period.

  • Dilutive EPS improved to $0.23 compared to a negative $1.39 in the prior year period.

  • Working capital surplus of $18.9 million compared to $8.3 million at December 31, 2023.

Year to Date 2024 Financial Highlights

  • Consolidated revenues of $484.7 million, compared to $555.4 million in the prior year.

  • Net income increased to $3.3 million, up from a $6.1 million loss in the prior year, a significant improvement of $9.3 million.

  • EBITDA of $6.7 million compared to an EBITDA of negative $4.2 million in the prior year, a significant improvement of $10.9 million.

  • Basic EPS improved to $0.74 compared to a negative $1.81 in the prior year.

  • Dilutive EPS improved to $0.69 compared to a negative $1.81 in the prior year.

"We are extremely pleased to report positive net income for the second consecutive quarter and record year-to-date net income, milestone achievements for the Company," said Michael Roper, Chief Executive Officer of Sadot Group. "Revenue growth in our core commodity trading business reached 11.6% year-over-year, in the latest three-month period, driven by increased transaction levels as we continued to expand our global commercial platform." The strength of our performance in the quarter and year-to-date periods reinforces our confidence in key strategies for driving growth and profitability within the nearly $2 trillion global agri-commodities market along with our commitment to delivering shareholder value."

Strategic and Operational Highlights

  • Completed 24 transactions of over 0.5 million metric tons of agri-commodities throughout 14 different countries during the third quarter.

  • Initiated trades from Sadot Brasil and Sadot Canada expanding the Company's global presence.

  • We are now a 100% franchise concept and have been able to reduce some overhead expenses accordingly.

  • Completed the sale of SuperFit foods.

  • Continuing due diligence with multiple parties for Pokémoto and Muscle Maker Grill.

  • Placed a deposit and in negotiations for the acquisition of an agricultural farming property in Indonesia.

All numbers disclosed in this report are the amounts attributable to Sadot Group Inc. and exclude the portion related to the non-controlling interests. All share based numbers are split adjusted.

Webcast Details

Date: Wednesday, November 13, 2024
Time: 10:30 am EDT/ 7:30 am PDT
To register, please use the following link:

https://audience.mysequire.com/webinar-view?webinar_id=c7e40f7d-e2b2-4540-b18f-f5c281ad6d90

* Please note that when logging into the Webcast, individuals must, when prompted to, "allow video and audio" access to their device to view and hear the call.

About Sadot Group Inc.

Sadot Group Inc. has rapidly established itself as an emerging player in the global food supply chain. Sadot Group provides innovative and sustainable supply chain solutions that address the world's growing food security challenges.

Sadot Group currently operates within key verticals of the global food supply chain including global agri-commodity origination and trading operations for food/feed products such as soybean meal, wheat and corn, and farm operations producing grains and tree crops in Southern Africa.

Sadot Group connects producers and consumers across the globe, sourcing agri-commodity products from producing geographies such as the Americas, Africa and the Black Sea and delivering to markets in Southeast Asia, China and the Middle East/North Africa region.

Sadot Group is headquartered in Burleson, Texas with subsidiary operations throughout the United States, Brazil, Canada, Colombia, India, Israel, Singapore, Ukraine, United Arab Emirates and Zambia. For more information, please visit www.sadotgroupinc.com.

Sadot Group, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)

September 30, 2024

December 31, 2023

$'000

$'000

ASSETS

Current assets:

Cash

962

1,354

Accounts receivable, net of allowance for doubtful accounts of $0.8 million and $0.2 million as of September 30, 2024 and December 31, 2023, respectively

38,333

52,920

Inventory

1,054

2,561

Assets held for sale

5,431

-

Other current assets

113,241

56,016

Total current assets

159,021

112,851

Right to use assets

137

1,284

Property and equipment, net

11,847

12,883

Goodwill

-

1,798

Intangible assets, net

-

2,833

Other non-current assets

22

46,442

Total assets

171,027

178,091

LIABILITIES AND EQUITY

Current liabilities:

Accounts payable and accrued expenses

40,346

50,167

Notes payable, current, net of discount of $0.1 million and $0.2 million as of September 30, 2024 and December 31, 2023, respectively

2,808

6,531

Operating lease liability, current

22

385

Deferred revenue, current

2,161

1,229

Liabilities held for sale

2,464

-

Other current liabilities

92,283

46,270

Total current liabilities

140,084

104,582

Contract liability, non-current

-

46,048

Notes payable, non-current

-

622

Operating lease liability, non-current

117

1,027

Deferred revenue, non-current

-

1,555

Total liabilities

140,201

153,834

Equity:

Common stock, $0.0001 par value, 20,000,000 shares authorized, 5,020,373 and 4,046,472 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively

1

-

Additional paid-in capital

111,650

107,992

Accumulated deficit

(83,912

)

(87,179

)

Accumulated other comprehensive (loss) / income

(180

)

8

Total Sadot Group Inc. shareholders' equity

27,559

20,821

Non-controlling interest

3,267

3,436

Total stockholders' equity

30,826

24,257

Total liabilities and stockholders' equity

171,027

178,091

Sadot Group, Inc.
Condensed Consolidated Statement of Operations and Other Comprehensive Income/ (Loss)
(Unaudited)

Three Months Ended September 30,

Nine Months Ended September 30,

2024

2023

2024

2023

$'000

$'000

$'000

$'000

Commodity sales

200,906

179,975

480,706

547,900

Company restaurant sales, net of discounts

479

1,937

2,628

6,725

Franchise royalties and fees

321

245

1,319

767

Franchise advertising fund contributions

12

16

40

52

Other revenues

16

-

16

13

Cost of goods sold

(199,271

)

(179,268

)

(480,074

)

(544,803

)

Gross profit

2,463

2,905

4,635

10,654

Impairment of goodwill

-

(828

)

-

(828

)

Impairment of intangible assets

-

(810

)

-

(810

)

Depreciation and amortization expenses

(49

)

(443

)

(421

)

(1,517

)

Franchise advertising fund expenses

(12

)

(16

)

(40

)

(52

)

Pre-opening expenses

-

(335

)

-

(371

)

Post-closing expenses

(91

)

(60

)

(120

)

(173

)

Stock-based expenses

(1,713

)

(1,075

)

(4,430

)

(5,667

)

Sales, general and administrative expenses

(4,245

)

(3,310

)

(8,770

)

(7,175

)

Loss from operations

(3,647

)

(3,972

)

(9,146

)

(5,939

)

Other income

-

1

19

252

Interest expense, net

(1,718

)

(301

)

(2,969

)

(320

)

Change in fair value of stock-based compensation

1,001

297

2,691

1,161

Warrant modification expense

-

(958

)

-

(958

)

Gain / (loss) on fair value remeasurement

5,461

(349

)

11,995

(349

)

Gain on sale of trading securities

-

-

518

-

Income / (Loss) Before Income Tax

1,097

(5,282

)

3,108

(6,153

)

Income tax expense

(3

)

(13

)

(9

)

(18

)

Net income / (loss)

1,094

(5,295

)

3,099

(6,171

)

Net loss attributable to non-controlling interest

69

112

169

112

Net income / (loss) attributable to Sadot Group Inc.

1,163

(5,183

)

3,268

(6,059

)

Net Income / (Loss) Per Share attributable to Sadot Group Inc.:

Basic

0.25

(1.39

)

0.74

(1.81

)

Diluted

0.23

(1.39

)

0.69

(1.81

)

Weighted-Average # of Common Shares Outstanding:

Basic

4,693,351

3,742,192

4,436,065

3,344,394

Diluted

5,011,339

3,742,192

4,707,964

3,344,394

Sadot Group, Inc.
Condensed Consolidated Statement of Operations and Other Comprehensive Income/ (Loss) (Continued)
(Unaudited)

Three Months Ended September 30,

Nine Months Ended September 30,

2024

2023

2024

2023

$'000

$'000

$'000

$'000

Net income / (loss)

1,094

(5,295

)

3,099

(6,171

)

Other comprehensive income / (loss)

Foreign exchange translation adjustment

(4

)

-

(1

)

-

Unrealized loss, net of income tax

(1

)

-

(187

)

-

Total other comprehensive loss

(5

)

-

(188

)

-

Total comprehensive income / (loss)

1,089

(5,295

)

2,911

(6,171

)

Comprehensive loss attributable to non-controlling interest

69

112

169

112

Total Comprehensive income / (loss) attributable to Sadot Group Inc.

1,158

(5,183

)

3,080

(6,059

)

Sadot Group, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)

Nine Months Ended September 30,

2024

2023

$'000

$'000

Cash Flows from Operating Activities

Net income / (loss)

3,099

(6,171

)

Adjustments to reconcile net income / (loss) to net cash used in operating activities:

Impairment of goodwill

-

828

Impairment of intangible assets

-

810

Depreciation and amortization

421

1,517

Stock-based expenses

4,430

5,667

Change in fair value of compensation

(2,691

)

(1,161

)

Warrant modification expense

-

958

Unrealized loss, net of income tax

(187

)

-

Foreign exchange translation adjustment

(1

)

-

Loss on disposal of assets

304

301

Bad debt expense

-

82

Transfer to assets held for sale

(481

)

-

Changes in operating assets and liabilities:

Accounts receivable, net

20,275

(61,155

)

Inventory

1,506

61

Other current assets

(57,206

)

(6,659

)

Other non-current assets

46,229

-

Accounts payable and accrued expenses

(9,532

)

55,869

Other current liabilities

46,278

397

Contract liability, non-current

(46,048

)

-

Operating right to use assets and lease liabilities, net

56

(46

)

Deferred revenue

528

23

Total adjustments

3,881

(2,508

)

Net cash provided by (used in) operating activities

6,980

(8,679

)

Cash Flows from Investing Activities

Deposit on farmland

(5,853

)

4,914

Investment from non-controlling interest

-

3,655

Purchases of property and equipment

(38

)

(12,447

)

Disposal of property and equipment

462

208

Net cash provided by / (used in) investing activities

(5,429

)

(3,670

)

Cash Flows from Financing Activities

Proceeds from notes payable

4,569

7,684

Proceeds from exercise of warrants

-

2,153

Repayments of notes payable

(6,512

)

(4,964

)

Net cash (used in) provided by financing activities

(1,943

)

4,873

Net Increase (Decrease) in Cash

(392

)

(7,476

)

Cash - beginning of period

1,354

9,898

Cash - end of period

962

2,422

Reconciliations of EBITDA and Other Non-GAAP Measures

EBITDA and EBITDA Margin are non-GAAP measures. The Company defines EBITDA as Net loss, adjusted for depreciation, amortization, interest income / (expense), and income taxes. The Company believes that EBITDA and EBITDA Margin, (collectively, the "Non-GAAP Measures") are useful metrics for investors to understand and evaluate its operating results and ongoing profitability because they permit investors to evaluate its recurring profitability from its ongoing operating activities.

EBITDA and EBITDA Margin, have certain limitations, and you should not consider them in isolation or as a substitute for analysis of its results of operations as reported under U.S. GAAP. The Company cautions investors that amounts presented in accordance with its definitions of any of the Non-GAAP Measures may not be comparable to similar measures disclosed by other issuers, because some issuers calculate certain of the Non-GAAP Measures differently or not at all, limiting their usefulness as direct comparative measures.

The following table presents a reconciliation of EBITDA from the most comparable U.S. GAAP measure, Net loss, and the calculations of the Net loss margin and EBITDA Margin for the three and nine months ended September 30, 2024 and 2023:

Three Months Ended September 30,

Nine Months Ended September 30,

2024

2023

2024

2023

$'000

$'000

$'000

$'000

Net income / (loss)

1,094

(5,295

)

3,099

(6,171

)

Adjustments to EBITDA:

Depreciation and amortization expenses

49

443

421

1,517

Interest (income) / expense, net

1,718

301

2,969

320

Income tax expense

3

13

9

18

EBITDA

2,864

(4,538

)

6,498

(4,316

)

EBITDA attributable to non-controlling interest

69

112

169

112

EBITDA attributable to Sadot Group Inc.

2,933

(4,426

)

6,667

(4,204

)

Gross Profit

2,463

2,905

4,635

10,654

Gross Profit attributable to Sadot Group Inc.

2,532

3,017

4,804

10,766

Net income / (loss) margin attributable to Sadot Group Inc.

0.5

%

(2.9)

%

0.6

%

(1.1)

%

EBITDA margin attributable to Sadot Group Inc.

1.5

%

(2.4)

%

1.4

%

(0.8)

%

Forward-Looking Statements

This press release may include "forward-looking statements" pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. To the extent that the information presented in this press release discusses financial projections, information, or expectations about our business plans, results of operations, products, or markets, or otherwise makes statements about future events, such statements are forward-looking. Such forward-looking statements can be identified by the use of words such as "should", "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," and "proposes." Although we believe that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors" and elsewhere in documents that we file from time to time with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained, and Sadot Group, Inc., does not undertake any duty to update any forward-looking statements except as may be required by law.

Investor Relations:

Frank Pogubila
SVP
Integrous Communications
W - 951.946.5288
E - IR@sadotco.com

SOURCE: Sadot Group Inc.



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.